The IPKat

MAY 12, 2024

The UPCKat trying to keep confidential information confidential in the UPC As part of our UPCKat reporting on the latest UPC developments, the IPKat brings readers a roundup of how the UPC is treating confidentiality and third party access to court documents.

Confidentiality 62

Confidentiality Art Patent Patent Application 62

IP and Legal Filings

JANUARY 21, 2022

Huawei and Verizon settle their FRAND patent dispute concerning the infringement claims in Texas, which was done shortly after the start of the trial. Through the settlementwhich was under confidential terms, the parties settle their patent dispute and lawsuits. Image Source: gettyimages].

Confidentiality 52

Confidentiality Marketing Marketing Licensing 52

The IPKat

JUNE 22, 2023

This is Part I of the detailed reporting on that Judgment. 2019) that the release term was in substance compensatory relief for TCL’s patent infringements when deciding worldwide FRAND terms. Mellor J indicated that this conclusion implies that the US court has jurisdiction to determine worldwide damages for patent infringement.

Patent Infringement 87

Patent Infringement Licensing Patent Litigation 87

SpicyIP

MARCH 11, 2024

Highlights of the Week Hot-Tubbing in Indian IP Litigation: Delhi High Court Issues Directives in High-Stakes Patent Infringement Case Image from [link] here Recently, the DHC issued directives regarding expert evidence in the Perjeta patent litigation. Anything we are missing out on? Please let us know in the comments below.

Trademark 59

Trademark Registration Copyright Patent 59

Patently-O

FEBRUARY 22, 2023

Patent assertion finance today is a multibillion-dollar business. [2] 2] Virtually nonexistent in the patent space in the U.S. litigation finance boom of the past 20 years—as has been widely reported, private equity now undergirds huge swaths of U.S. Patent assertion finance today is a multibillion-dollar business. [2]

Litigation 126

Litigation Reporting Settlement Government 126

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

The biosimilar market also exhibited continued growth, with multiple biosimilar developers reporting strong sales of biosimilars through 2021. Several sources also report that Nyvepria ™ , Pfizer’s Neulasta ® biosimilar, hit the market in late 2020 or early 2021. Reported Discount at Launch. No earlier than 2023 per settlement.

Litigation 52

Litigation Settlement Patent Marketing 52

LexBlog IP

APRIL 3, 2023

This decision indicates that an SEP owner sometimes might need to provide information to a prospective licensee (under a confidentiality agreement), although that may not be necessary for an experienced licensee who can consult existing patent licenses they have entered with others. non-discriminatory] part of FRAND).

Licensing 52

Licensing Technology Intellectual Property Patent 52